Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: The quality evaluation system establishment of mesenchymal stromal cells for cell-based therapy products

Fig. 3

The growth potential of HUCMSCs and B16F10 cells. a The red nuclei cells were identified as proliferating cells in EDU immunostaining for proliferation rate. b FCM analysis data for cell cycle. c HUCMSCS had a much lower proliferation rate than that of tumor cell line B16F10. d The percentage of B16F10 in the S phase was statistically higher, but in G1 and G2 phases were both lower than that of HUCMSCs. e HUCMCs had a “S” growth curve, but the growth of HUCMSCs was inferior to B16F10 (**p < 0.01; ***p < 0.001)

Back to article page